[National Institutes of Health](https://www.nih.gov)

July 14, 2026 (Estimated)

Estimated total program funding: $19,100,000; ~6 awards expected.

Supports the continuation of NCI biospecimen banks for clinical trials, enabling high-quality biospecimen collection and translational cancer research.

Limited competition; only current NCTN/EET biobank awardees eligible.

--- ## Description This forecasted opportunity from the National Cancer Institute (NCI), part of the NIH, will support the continued operation of two major biospecimen banking resources: the National Clinical Trials Network (NCTN) Biospecimen Banks and the Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank). These resources are critical for collecting, processing, storing, and distributing clinically annotated human biospecimens from NCI-funded clinical trials. The aim is to ensure ongoing access to high-quality biospecimens for translational cancer research, biomarker development, and scientific discovery. The NCTN Biobanks primarily support large, multi-site clinical trials in adult and childhood cancers, facilitating research on disease mechanisms, therapeutic response, and clinical outcomes. The EET Biobank focuses on early-phase and experimental clinical trials, supporting studies on investigational new drugs (INDs), biomarker assay development, drug action, and resistance mechanisms. This is a limited competition opportunity, restricted to institutions/entities that currently operate NCTN or EET biobanks funded under previous related RFAs. --- ## Due Dates - Estimated Application Due Date: July 14, 2026 *All dates are projected based on the annual cycle; check the program page for updates.* --- ## Funding Amount - Estimated total program funding: $19,100,000 - Expected number of awards: 6 - Award ceiling and floor: Not specified - Funding Instrument: Cooperative Agreement (U24) - Project start date: Estimated April 1, 2027 --- ## Eligibility - **Eligible Applicants:** Limited to current recipients of: - NCTN biobank awards funded under RFA-CA-20-002 - EET biobank awards funded under RFA-CA-20-003 - Only institutions/entities that already operate the relevant NCTN or EET biobank are eligible. - No cost sharing or matching requirement. --- ## Application Process - This is a forecasted opportunity; applications are not being solicited at this time. - The Notice is provided to allow potential applicants time to develop collaborations and responsive projects. - Applications will be peer-reviewed and funded if meritorious. - Monitor the [grants.gov opportunity page](https://www.grants.gov/search-results-detail/361134) for updates and the official application announcement. --- ## Additional Information - This is a limited competition; not open to new applicants. - Supports continuation, not establishment, of biospecimen banks. - Focus on maintaining and enhancing national resources for cancer clinical trial biospecimens. --- ## External Links - [NIH Home Page](https://www.nih.gov) - [Grants.gov Opportunity Listing](https://www.grants.gov/search-results-detail/361134) --- ## Contact Information | Contact | Email | Phone | |------------------------|--------------------------------------|---------------| | NCI DCTD CDP PIRB NOFO | [NCICDPNOFO@mail.nih.gov](mailto:NCICDPNOFO@mail.nih.gov) | 240-276-7782 |

Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)

Sign in to see full grant listing